J Infect Dis

References in J Infect Dis:

Search this table:

Title	Authors	Year
Correlation of e antigen, DNA polymerase activity, and Dane particles in chronic benign and chronic active type B hepatitis infections.	Tong MJ, Stevenson D, Gordon I	1977
Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy.	Lin PF, Samanta H, Rose RE, Patick AK, Trimble J, Bechtold CM, Revie DR, Khan NC, Federici ME, Li H	1994
Ionic requirements of the DNA polymerase associated with serum hepatitis B antigen.	Hirschman SZ, Garfinkel E	1977
Characterization of the DNA polymerase and thymidine kinase genesof herpes simplex virus isolates from AIDS patients in whom acyclovirand foscarnet therapy sequentially failed.	Schmit I, Boivin G	1999
Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance.	Maeda Y, Venzon DJ, Mitsuya H	1998
Discordant e antigen, DNA polymerase activity, and Dane particle responses in two patients representing an index case-contact case pair with hepatitis B virus infection.	Perrillo RP, Gelb LD, Milligan WH, Wellinghoff W, Aach RD	1977
Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy.	Brumme ZL, Brumme CJ, Chui CK, Mo T, Wynhoven B, Woods CK, Henrick BM, Hogg RS, Montaner JS, Harrigan PR	2007
Lack of association between infection with a novel human coronavirus (HCoV), HCoV-NH, and Kawasaki disease in Taiwan.	Chang LY, Chiang BL, Kao CL, Wu MH, Chen PJ, Berkhout B, Yang HC, Huang LM	2006
Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro.	Miller MD, Anton KE, Mulato AS, Lamy PD, Cherrington JM	1999
Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.	Miller MD, Margot NA, Lu B, Zhong L, Chen SS, Cheng A, Wulfsohn M	2004
e antigen and antibody, DNA polymerase, and inhibitors of DNA polymerase in acute and chronic hepatitis.	Cappel R, DeCuyper F, Van Beers D	1977
Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group.	Harrigan PR, Stone C, Griffin P, Nájera I, Bloor S, Kemp S, Tisdale M, Larder BA	2000
Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).	Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, Danner SA, Mulder J, Loveday C, Christopherson C	1995
Filtration and immunoprecipitation in the elimination of DNA polymerase activity associated with bacterial contamination of sera positive for hepatitis B e antigen and its corresponding antibody.	Perrillo RP, Gelb LD, Wellinghoff W, Aach RD	1978
A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors.	Tatarowicz WA, Lurain NS, Thompson KD	1992
Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus.	Chou S, Lurain NS, Thompson KD, Miner RC, Drew WL	2003
Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy.	De Antoni A, Foli A, Lisziewicz J, Lori F	1997
Novel mutation of human DNA polymerase gamma associated with mitochondrial toxicity induced by anti-HIV treatment.	Yamanaka H, Gatanaga H, Kosalaraksa P, Matsuoka-Aizawa S, Takahashi T, Kimura S, Oka S	2007

Showing 1 to 18 of 18 entries